Vascular Medicine News

A speaker reported that improved differentiation of resistant vs. refractory hypertension is essential in choosing optimal antihypertensive treatment, as the two represent different disease states of elevated blood pressure.

CDC data show a spike in infective endocarditis deaths among young adults despite an overall decline in such deaths from 1999 to 2020, with researchers citing the role of comorbid opioid use disorder.

SAN DIEGO — Individuals treated with first-generation Bruton tyrosine kinase inhibitors with preexisting cardiovascular disease had significantly higher odds of developing cardiovascular adverse events, study results showed.

Global CV mortality and the prevalence of important cardiometabolic risk factors increased through 2022, with high BP remaining the strongest contributor, according to the 2023 update to the Global Burden of Disease special report on CVD.

Direct oral anticoagulants have become the standard of care for stroke prevention in patients with atrial fibrillation, among other indications, but factor XI/XIa inhibitors may have the potential to usurp them due to safety profiles.

Results published in The Journal of Bone & Joint Surgery showed the use of tranexamic acid during total joint arthroplasty did not increase the risk for thrombotic complications in patients with a history of venous thromboembolism.

Presentations on the latest cardiometabolic research, panel discussions and updated practice recommendations are among this year’s highlights at the 21st World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease.

One spouse in a heterosexual marriage having hypertension was associated with increased likelihood for the other spouse to have it as well, especially in India and China, but odds were also elevated among couples in the U.S. and England.

Among 22 pairs of twins, those who were randomly assigned to a vegan diet had improvements in several cardiovascular measures vs. their twin who was assigned to a healthy omnivore diet, according to findings published in JAMA Network Open.

When added to background therapy for pulmonary arterial hypertension, sotatercept improves 6-minute walk distance and WHO functional class vs. placebo, according to an evidence report by the Institute for Clinical and Economic Review.